Researchers of rare and orphan diseases face unique challenges when it comes to drug development. Enrolling in a clinical trial can lead to high costs for patients, as well as reliance on a caregiver or friend. PRA Health Sciences has developed a toolkit to help clinical trial sponsors identify weak points and risks, with the overall goal of improving drug development and increasing patient enrollment.
Scott Schleibner, of PRA Health Sciences remarks, “We chose to develop this toolkit as a free, open-access set of tools for sponsors, patients, and patient organizations to use. Our aim is to ensure that all clinical trials – regardless of the trial phase, indication, geography, or sponsor – include the patient perspective within the study development stage, so that burdens to participation can be minimized to ensure patients can, and will, enroll.” Read more here.
(Source: Jenni Spinner, 4/5/21)